FDA grants accelerated approval to dostarlimab for rectal cancer

The FDA cleared GSK's Jemperli as a stand-alone treatment that may spare some rectal cancer patients surgery.

Objective Facts

The FDA granted accelerated approval on October 19, 2026, to GSK's PD-1 inhibitor dostarlimab (Jemperli) as monotherapy for adults with stage II or III mismatch repair-deficient or microsatellite instability-high locally advanced rectal cancer. Patients receive 500 mg intravenously every three weeks for up to nine cycles, according to The ASCO Post. In the single-arm AZUR-1 trial of 154 patients, the primary endpoint of a sustained clinical complete response at 12 months was met by 47% of patients by independent central review and 68% by investigator review, and GSK said no responders had relapsed after a median follow-up of more than two years. An earlier 50-patient Memorial Sloan Kettering study found a 93% sustained response rate. The FDA said longer follow-up is needed to establish how long responses last, AJMC reported.

Deep Dive

Standard care for locally advanced rectal cancer usually combines chemotherapy, radiation and surgery, which can damage bowel, urinary and sexual function and fertility, Cure Today and AJMC reported. Andrea Cercek of Memorial Sloan Kettering told Fierce Pharma that about 30% of patients under standard care need a permanent colostomy. Her earlier 50-patient study at MSK, in which no patient needed chemoradiation or surgery, led to the larger AZUR-1 trial. An FDA advisory committee voted 8 to 5 in 2023 that single-arm data could support approval in this setting, PharmExec reported. Panelist Jorge Garcia of Case Western Reserve voted no, saying the data were not enough to characterize risks and benefits in a curative setting, according to OncoTherapy Network. The population is small. AJMC cited FDA figures putting dMMR or MSI-H tumors at about 3% of locally advanced rectal cancers, while GSK estimates 5% to 10% of all rectal cancers. The trial has no control arm, and the independent review rate of 47% trails the investigator rate of 68%. GSK says the central figure is still maturing, with 38 more patients holding a complete response but less than 12 months of follow-up. Hesham Abdullah, GSK's global head of oncology R&D, told Fierce Pharma that investigator assessments are probably the most relevant in practice. Serious adverse reactions occurred in 20% of patients and 3% stopped treatment, GSK said. Michael Sapienza, CEO of the Colorectal Cancer Alliance, said biomarker testing at diagnosis will decide who is eligible. Full AZUR-1 interim data are due at the ESMO Congress this month. Continued approval depends on confirmatory evidence, and Fierce Pharma pointed to the phase 3 AZUR-2 trial, expected to read out in 2028. Under Project Orbis, regulators in Canada, Israel, Switzerland and the UK are still reviewing the drug, The ASCO Post reported. Medical Daily noted that cost and insurance coverage remain unclear, and that insurers may require prior authorization and proof of test results.

OBJ SPEAKING

Create StoryTimelinesVoter ToolsRegional AnalysisPolicy GuideAll StoriesCommunity PicksUSWorldPoliticsBusinessHealthEntertainmentTechnologyAbout

FDA grants accelerated approval to dostarlimab for rectal cancer

The FDA cleared GSK's Jemperli as a stand-alone treatment that may spare some rectal cancer patients surgery.

Oct 20, 2026· Updated Oct 21, 2026
What's Going On
  • On October 19, 2026, the FDA granted accelerated approval to GSK's dostarlimab (Jemperli) for adults with previously untreated stage II or III rectal cancer that is dMMR or MSI-H, confirmed by an FDA-authorized test.
  • The decision rests on interim results from AZUR-1, a single-arm phase 2 trial of 154 patients, in which independent reviewers found a 12-month sustained complete response in 47% of 116 evaluable patients and investigators found 68% of 144.
  • According to The ASCO Post, 110 patients (71%) needed no treatment beyond dostarlimab and had not progressed at a median follow-up of 26.3 months.
  • The FDA acted about four months ahead of its February 2027 goal date, using priority review and a Commissioner's National Priority Voucher, AJMC reported.
  • Fierce Pharma reported that GSK must still confirm the benefit, pointing to the phase 3 AZUR-2 trial in colon cancer, with a readout expected in 2028.
◆ All Sources (10)
OncLive - FDA Approves Dostarlimab for dMMR/MSI-H Locally Advanced Rectal CancerThe ASCO Post - FDA Approves Dostarlimab for MSI-H/dMMR Locally Advanced Rectal CancerAJMC - FDA Grants Accelerated Approval to Dostarlimab for dMMR Rectal CancerFierce Pharma - GSK's Jemperli scores FDA approval in rectal cancer, backed by high complete response rateBecker's Hospital Review - FDA approves surgery-sparing immunotherapy for rectal cancerMedical Daily - Jemperli Wins Accelerated FDA Approval for a Rectal Cancer Subtype as Most Trial Patients Avoided SurgeryCure Today - FDA Approves Jemperli for dMMR Locally Advanced Rectal CancerPharmExec - FDA Approves Jemperli for MSI-H/dMMR Locally Advanced Rectal CancerOncoTherapy Network - ODAC Votes 8-5 in Favor of Dostarlimab in Advanced Rectal CancerGSK - Jemperli approved in US as first and only immunotherapy for adults with MSI-H/dMMR locally advanced rectal cancer
Objective Deep Dive

Standard care for locally advanced rectal cancer usually combines chemotherapy, radiation and surgery, which can damage bowel, urinary and sexual function and fertility, Cure Today and AJMC reported. Andrea Cercek of Memorial Sloan Kettering told Fierce Pharma that about 30% of patients under standard care need a permanent colostomy. Her earlier 50-patient study at MSK, in which no patient needed chemoradiation or surgery, led to the larger AZUR-1 trial. An FDA advisory committee voted 8 to 5 in 2023 that single-arm data could support approval in this setting, PharmExec reported. Panelist Jorge Garcia of Case Western Reserve voted no, saying the data were not enough to characterize risks and benefits in a curative setting, according to OncoTherapy Network.

The population is small. AJMC cited FDA figures putting dMMR or MSI-H tumors at about 3% of locally advanced rectal cancers, while GSK estimates 5% to 10% of all rectal cancers. The trial has no control arm, and the independent review rate of 47% trails the investigator rate of 68%. GSK says the central figure is still maturing, with 38 more patients holding a complete response but less than 12 months of follow-up. Hesham Abdullah, GSK's global head of oncology R&D, told Fierce Pharma that investigator assessments are probably the most relevant in practice. Serious adverse reactions occurred in 20% of patients and 3% stopped treatment, GSK said. Michael Sapienza, CEO of the Colorectal Cancer Alliance, said biomarker testing at diagnosis will decide who is eligible.

Full AZUR-1 interim data are due at the ESMO Congress this month. Continued approval depends on confirmatory evidence, and Fierce Pharma pointed to the phase 3 AZUR-2 trial, expected to read out in 2028. Under Project Orbis, regulators in Canada, Israel, Switzerland and the UK are still reviewing the drug, The ASCO Post reported. Medical Daily noted that cost and insurance coverage remain unclear, and that insurers may require prior authorization and proof of test results.

◈ Tone Comparison

Coverage of the approval is clinical rather than political. The FDA's Angelo de Claro, quoted by AJMC, called it a "groundbreaking option that avoids surgery, radiation and chemotherapy," while Fierce Pharma's Angus Liu put more weight on the gap between central and investigator review figures. Medical Daily's Elena Vega stressed that the data are interim and that the results do not show the drug is a cure.